Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

The great escape: Is immune evasion required for tumor progression?

Nature Medicine volume 5, pages 874–875 (1999)Cite this article

Abstract

A study on page 938 reports the identification of an ovarian and uterine tumor-associated ligand, RCAS1, which inhibits growth of activated T lymphocytes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Upper panel, complex three-way interactions between tumor cells, their microenvironment and the immune system.

References

  1. Seliger, B., Maeurer, M.J. & Ferrone, S. TAP off—tumors on. Immunol. Today 18, 292–299 (1997).

    CAS  PubMed  Google Scholar 

  2. Pitti, R.M, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699– 703 (1998).

    Article  CAS  Google Scholar 

  3. Walker, P.R., Saas, P. & Dietrich, P.-Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol. 10, 564– 572 (1998).

    Article  CAS  Google Scholar 

  4. Gimmi, C.D. et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Med. 2, 1367–1370 (1996).

    Article  CAS  Google Scholar 

  5. Levy, L.S. & Bost, K.L. Mechanisms that contribute to the development of lymphoid malignancies: roles for genetic alterations and cytokine production. Crit. Rev. Immunol. 16, 31– 57 (1996).

    Article  CAS  Google Scholar 

  6. Nakashima M., Sonoda K. & Watanabe K. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen, RCAS1. Nature Med. 5, 938–942 ( 1999).

    Article  CAS  Google Scholar 

  7. Greenfield, E.A., Nguyen, K.A. & Kuchroo, V.K. CD28/B7 costimulation: a review. Crit. Rev. Immunol. 18, 389–418 (1998).

    Article  CAS  Google Scholar 

  8. Van den Eynde, B.J. & van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol. 9, 684–693 (1997).

    Article  CAS  Google Scholar 

  9. Seino, K.-I., Kayagaki, N., Okumura, K. & Yagita, H. Antitumor effect of locally produced CD95 ligand. Nature Med. 3, 165–170 (1997).

    Article  CAS  Google Scholar 

  10. Disis, M.L. & Cheever, M.A. HER-2/neu oncogenic protein: issues in vaccine development. Crit. Rev. Immunol. 18, 37–45 (1998).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Walter & Eliza Hall Institute for Medical Research, P.O. Royal Melbourne Hospital, Victoria, 3050, Australia

    Andreas Villunger & Andreas Strasser

Authors
  1. Andreas Villunger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Strasser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Villunger, A., Strasser, A. The great escape: Is immune evasion required for tumor progression?. Nat Med 5, 874–875 (1999). https://doi.org/10.1038/11311

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/11311

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing